182 results about "Peptide conjugate" patented technology

The present invention relates generally to the field of medicine. More particularly, the present invention relates to polypeptide conjugates, compositions and methods for promoting immune tolerance to CRISPR-Cas (clustered regularly spaced short palindromic repeats-CRISPR associated proteins) systems for use in genomic engineered gene therapy.

Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide including at least one cationic domain comprising at least 4 amino acid residues and at least one hydrophobic domain comprising at least 3 amino acid residues, provided that the peptide includes a total of 7 to 40 amino acid residues and does not include any artificial amino acid residues; and the oligonucleotide including a total of 12 to 40 contiguous nucleobases, where at least 12 contiguous nucleobases are complementary to a target sequence in a human dystrophin gene.

To provide peptide ligands, and peptide complexes comprising the peptide ligands conjugated to a second peptide.SOLUTION: The present invention provides a peptide ligand that binds to Nectin-4 present on a cancer cell, or a pharmaceutically acceptable salt thereof, the peptide ligand comprising a polypeptide comprising at least three reactive groups separated by at least two loop sequences, and a molecular scaffold that forms covalent bonds with the reactive groups of the polypeptide, such that at least two polypeptide loops are formed on the molecular scaffold, wherein the polypeptide is a modified derivative of a specific sequence.SELECTED DRAWING: None

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula(SEQ ID NO: 1)X1X2X3X4X5GVX6AKAGVX7NX8FKSESY(I)(SEQ ID NO: 2)(X9)nGVX10AKAGVX11NX12FKSESY(II)(SEQ ID NO: 3)YKX13LRRX14APRWDX15PLRDPALRX16X17L(III)(SEQ ID NO: 4)YKX18LRR(X19)nPLRDPALRX20X21L(IV)(SEQ ID NO: 5)IKLSGGVQAKAGVINMDKSESM(V)(SEQ ID NO: 6)IKLSGGVQAKAGVINMFKSESY(VI)(SEQ ID NO: 7)IKLSGGVQAKAGVINMFKSESYK(VII)(SEQ ID NO: 8)GVQAKAGVINMFKSESY(VIII)(SEQ ID NO: 9)GVRAKAGVRNMFKSESY(IX)(SEQ ID NO: 10)GVRAKAGVRN(Nle)FKSESY(X)(SEQ ID NO: 11)YKSLRRKAPRWDAPLRDPALRQLL(XI)(SEQ ID NO: 12)YKSLRRKAPRWDAYLRDPALRQLL(XII)(SEQ ID NO: 13)YKSLRRKAPRWDAYLRDPALRPLL(XIII)wherein X1 to X21 and n can have various different valuesand wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end.

Provided herein are conjugates comprising a promoter peptide conjugated to an agent, such as an antibody or antigen-binding fragment thereof. The promoter peptides promote internalization of an agent (e.g., an antibody or antigen binding fragment thereof). The promoter peptides may also promote internalization of a target protein into a cell when coupled to an agent that binds to the target protein (e.g., a receptor). Also provided are methods of using the conjugates provided herein, for example, for promoting uptake of an antibody or antigen-binding fragment thereof into a cell, for promoting uptake of a target protein into a cell.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.

Featured are devices, systems, and methods of use for detecting binding of polynucleotide-peptide conjugate-major histocompatibility complex (pMHC) monomers to a T cell receptors (TCR) on a T cell, and the use of a peptide library to detect binding of antigenic peptides in a pMHC monomer to a T cell receptor (TCR) on a T cell.

A carrier peptide conjugate comprising one or more carrier peptide groups and one or more functional groups; each carrier peptide group is linked to at least one of the functional groups or at least one further carrier peptide group via at least one linking group, and each functional group is linked to at least one of the carrier peptide groups or at least one further functional group via at least one linking group; the length of each carrier peptide group is 5-40 amino acid residues, and each carrier peptide group contains one or more amino acid sequence segments which are connected in series and are shown as a formula (I); each functional group is independently one of a functional oligonucleotide group and a delivery aid group, and at least one functional group is a functional oligonucleotide group. The carrier peptide conjugate provided by the invention can be effectively targeted to the kidney or kidney tissue.

Provided herein are Camptothecin Conjugates, Camptothecin-Linker Compounds, Camptothecin Compounds, intermediates thereof, and method of preparing the same. Also provided herein are methods of treating cancer and autoimmune diseases with the Conjugates described herein.

Provided are compositions and methods that include binding partners that specifically bind to a peptide conjugate / MHC complex comprising a peptide conjugate that is formed by the covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies and antibody derivatives that specifically bind to the peptide conjugate / MHC complexes.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

The present invention relates to a linker compound having a fused nitrogen-containing heteroaromatic ring and a vinyl substituent for conjugating to a protein or peptide. The present invention further relates to a conjugate comprising the linker and an active agent and to a conjugate comprising the linker, a protein or peptide, and an active agent, such as a drug or labelling moiety. More specifically, the conjugate may be an antibody conjugate, such as an antibody drug conjugate (ADC).

Compositions, methods and treatment regimens for mutant fibroblast growth factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

An embodiment of the present invention relates to: a cancer antigen peptide nanostructure comprising an assembly of cancer antigen peptides conjugated with deoxycholic acid; a method for preparing same; and use thereof. The inventors of the present invention confirmed that the nanostructure of the present invention effectively stimulates the maturation of dendritic cells, migrates to lymph nodes, and activates T cells. Also, in a cancer cell model, significant infiltration of cytotoxic T lymphocytes into primary tumors was observed, and an anti-metastatic effect was confirmed. Therefore, the nanostructure according to the present invention can be effectively used as a promising immunotherapy platform that can be applied to various intractable cancers.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, conjugated with polyethylene glycol (PEG) and / or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a generated PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization to further optimize activity, and methods for using such structurally-stabilized peptide conjugates in the prevention and treatment of an Ebolavirus infection or disease in a subject (e.g., human, non-human primate, or fruit bat). The disclosure also relates to methods of using such structurally-stabilized peptides and conjugates in the prevention and treatment of a Marburg virus infection, a Bombali ebolavirus infection, or a Mengla dianlovirus infection in a subject.

The present invention relates to peptide conjugates that comprise a plant-derived oligopeptide capable of crossing the blood-brain barrier (BBB) and a therapeutic or diagnostic agent. The BBB-penetrating oligopeptide is an oligopeptide according to Formula I, Asp–R2–Gly–Leu–R5–R6–R7–Leu–Gly–R10–R11–R12, wherein R2 represents Arg, Lys, Cyt, D-Arg or Orn; R5 represents Phe, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, Orn, 4-aminophenylalanine or 3-phenylpropionate; R6 represents Pro, Leu, Glu or Lys; R7 represents Phe or Trp; R10, R11 and R12 each independently represent Lys, Arg or Orn; or an oligopeptide according to Formula II, Glu–R2'–R3'–Gly–R5'–R6'–Glu–R8'–R9'–R10'–Glu–R12'–Leu–Pro–Gly, wherein R2', R3', R8', R10' and R12' each independently represent Lys, Arg or Orn; R5' represents Phe, Ile, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, 4-aminophenylalanine, or 3-phenylpropionate; R6' represents Met, Leu, Ile, Asn, norleucin, D-norleucin, seleno- methionine or D / L-2-hydroxy-(4-methylseleno)butanoic acid; and R9' represents Leu or Ile. The conjugates comprising a BBB-penetrating oligopeptide compound and a therapeutic agent can be used in treatments for diseases of the central nervous system (CNS). Furthermore, conjugates with a BBB-penetrating oligopeptide compound and a diagnostic agent can be used in both in vivo and in vitro diagnostic methods.

The present invention relates to a Trolox-peptide conjugate having a structure in which Trolox and a peptide are chemically bonded. The Trolox-peptide conjugate not only very effectively inhibits the activity of 5α-reductase, but also inhibits the death of papilla cells and keratinocytes, promotes the growth thereof, and has antioxidative effects, and thus can remarkably promote hair formation while avoiding or preventing hair loss.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The present invention relates to c-Met targeting peptides and derivatives thereof, to pharmaceutical compositions, drug-peptide conjugates comprising the peptides or derivatives thereof, and their use in the detection, prevention or treatment of diseases (e.g., cancer). In addition, the peptide or the derivative thereof can increase the water solubility of the drug.

The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS- COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.

Provided herein are antibodies, antigen-binding portions thereof, and antibody peptide conjugates that specifically bind to neuropilin-1 (NRP1) and various compositions of such antibodies, antigen-binding portions, and antibody-peptide conjugates. The disclosure also provides nucleic acids encoding the antibodies, antigen-binding portions thereof, or antibody peptide conjugates; cells comprising the nucleic acids; and methods for producing the antibodies, antigen-binding portions thereof, or antibody peptide conjugates. Also provided are methods for using the antibodies or antigen-binding portions thereof in therapeutics and diagnostics for cancer.

To provide a selection platform that exploits the physiology of the choroid plexus to identify molecular transport system (MTS) peptides capable of holding various functional cargos in the cerebrospinal fluid and distributing the cargos to cells of the CNS.SOLUTION: Provided are MTS peptides or targeting peptides comprising a specific amino acid sequence. Provided are compositions comprising a peptide, the peptide comprising a first MTS peptide conjugated to a cargo. Methods of using the MTS peptides are also provided. For example, provided is a method for transporting cargo to the CNS, the method comprising administering one or more of the disclosed compositions to a subject in need thereof, the peptide conjugated to the cargo entering the CNS.SELECTED DRAWING: None

Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

Described herein is a 3D-printed scaffold comprising a peptide-polymer conjugate, the peptide-polymer conjugate having the structure: X—Y—Z—Y—X, wherein X is a biologically active peptide, Y is a linker moiety, and Z is a biocompatible and biodegradable polymer.

The present invention relates to multivalent peptide conjugates, and pharmaceutical compositions, methods of preparation, and methods of use thereof.

The present invention is a multispecific polypeptide conjugate, an isolated polynucleotide encoding the same, a pharmaceutical composition comprising the same and uses thereof.

This document discloses MTS peptides or targeting peptides. MTS peptides comprising the amino acid sequence of any one of SEQ ID NO: 1-12 are disclosed. Compositions comprising peptides, wherein the peptides comprise a first MTS peptide conjugated to a cargo, are disclosed. Methods of using MTS peptides are also disclosed. For example, a method of transporting cargo to a CNS is disclosed, the method comprising administering one or more of the disclosed compositions to a subject in need, wherein the cargo-conjugated peptide enters the CNS.